Hairloss Treatments discussion on upcoming treatments by Bloomberg
    9/3/2026

    From the encyclopedia
    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    RU58841 →

    Experimental topical anti-androgen sold as a research chemical

    At a glance
    In this general discussion post, the primary subjects mentioned are the tone is 😐 neutral.

    Other terms

    The conversation discusses future hair loss treatments, including Minoxidil, finasteride, RU58841, and the potential release of Cosmo (breezula) next year. There is skepticism about the timeline for Cosmo's filing.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community July 1st - Early H2 - Breezula

      in Treatment  1 upvotes 1 year ago
      Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

      community Why Breezula Won’t Work for Everyone.

       30 upvotes 8 months ago
      Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.

      community Breezula 6 Month Topline Phase III Results Released

       172 upvotes 9 months ago
      Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

      community Has anyone seen the data on this 539% boost breakthrough?

       866 upvotes 6 months ago
      Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

    Related Research

    6 / 6 results

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

      research Experimental and early investigational drugs for androgenetic alopecia

      11 citations , July 2017 in “Expert Opinion on Investigational Drugs”
      This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

      research Тіе Modern treatment of androgenetic alopecia

      February 2017 in “Vestnik dermatologii i venerologii”
      This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.

      research Treatments for Androgenetic Alopecia and Alopecia Areata

      72 citations , January 2001 in “Drugs”
      This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

      research Hair growth and rejuvenation: An overview

      81 citations , June 2010 in “Journal of Dermatological Treatment”
      This review discusses recent advancements in hair rejuvenation strategies and assesses the potential of herbal drugs as safer alternatives, but reports no new clinical results.